RetiSpec
its AI-driven hyperspectral eye test analyzes retinal spectral signatures associated with Alzheimer's disease, recently closing a $10 million USD funding round to advance commercialization, with the underlying imaging technology documented in a dedicated patent filing.
- Country
- Canada
Growth
AI hyperspectral Alzheimer's eye test
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Retinal biomarkers for neurodegenerative disease | diagnostics-medtech | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.